By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AngioGenex Inc. 

425 Madison Avenue
Suite 902)
New York  New York  10017  U.S.A.
Phone: 212-874-6608 Fax: 212-874-5027




Company News
AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 2/3/2009 1:19:16 PM
AngioGenex Reviews 2008 Achievements and Sets Goals for 2009 11/26/2008 8:11:57 AM
AngioGenex Appoints New CEO to Direct Development of Anti-Cancer Drugs 6/10/2008 8:44:53 AM
Benezra Report in Nature Biotechnology Validates AngioGenex's Drug Development Platform by Demonstrating Tumor Suppression Through Id Protein Inhibition 1/8/2008 10:36:00 AM
William Garland Joins AngioGenex's New Board of Directors 1/7/2008 10:47:03 AM
AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer 10/16/2007 8:42:47 AM
AngioGenex European Listing Approved -- Company's Shares Now Trading on the Frankfurt Stock Exchange under Symbol 'TLE' 6/21/2007 11:48:51 AM
AngioGenex Engages London & Pacific Healthcare to Assist in Attracting Investment Funding 5/4/2007 10:43:49 AM
AngioGenex, BioCheck Collaboration Produces Novel Antibodies, Revenue and Progress toward a Cancer Diagnostic 5/3/2007 12:48:25 PM
AngioGenex Listing Approved-Trading Under Symbol AGGX.OB 3/7/2007 2:13:37 PM